Celia Hart

General Partner

CELIA HAS MORE THAN 15 YEARS’ EXPERIENCE IN PRIVATE EQUITY. SHE JOINED THE TEAM IN 2005 AND IS RESPONSIBLE FOR THE HEALTHCARE SECTOR AND THE SUPERNOVA 2 FUND.

Before joining Supernova Invest, Celia held several high-level positions at Cambridge Antibody Technology (Medimmune since its acquisition by AstraZeneca), one of the stars of UK biotech.
She played a role in developing a number of therapeutic antibodies, including some in co-development with international industrial partners. Celia holds a master’s degree in chemistry from the University of Geneva (Switzerland), a PhD from the University of Oxford, and an MBA from Grenoble École de Management (France).
Celia is a member of the board of directors or supervisory board of several companies, including Algaia, Carthéra, NH Theraguix, Diabeloop, Enobraq, Keranova, LX Repair, and Uromems.

celia.hart@supernovainvest.com